Perhaps not squarely on certain peoples radars in these parts OSI Pharmaceuticals (NASDAQ: OSIP) is sometimes not uttered in the same breath by some when referring to public CO companies, easy to do I suppose since corporate headquarters are actually located in Melville, NY however, a very significant campus is here in Boulder, housing both [...]

• 295http://clsdf.com/2008/01/osi-pharma-175mm-in-new-debt-more%e2%80%a6/OSI+Pharma%3A+%24175MM+in+New+Debt+%26amp%3B+More%E2%80%A62008-01-16+15%3A33%3A00admin

QUESTION: What do ZostaVax®, Kineret® and Macugen® have in common… ANSWER: They are all FDA approved first-in-class commercialized products originating from University of Colorado intellectual property. Want to learn more about these products and the rich product pipeline portfolio at the University of Colorado? Then take a listen to this podcast featuring David Allen, Ph.D., [...]

• 213http://clsdf.com/2007/09/3-commercialized-products-counting/3+Commercialized+Products+%26amp%3B+Counting%212007-09-08+23%3A04%3A00admin

At their quarterly conference call OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced a planned exit of their recent $650M Eyetech acquisition. OSI bought Eyetech primarily for the age related macular degeneration (AMD) drug Macugen. Macugen sales for the quarter rapidly and dramatically declined, reaching only $9M in sales relative to $87M for the previous two quarters. [...]

• 134http://clsdf.com/2006/11/black-eye-for-macugen/Black+Eye+For+Macugen2006-11-08+16%3A05%3A00admin

There are many reasons why here in Colorado we keep a careful eye on Macugen, no pun intended… OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced interim Phase II study results showing that injections of Macugen® resulted in better visual acuity outcomes in patients with macular edema due to central retinal vein occlusion compared with those receiving [...]

• 96http://clsdf.com/2006/06/positive-phase-ii-data-for-macugen%c2%ae/Positive+Phase+II+Data+for+Macugen%C2%AE2006-06-02+14%3A57%3A00admin